Open access · CC-BY
via OpenAlex
7581 Periodic Administration of Quercetin and Dasatinib Alleviates Skeletal Fragility in the INS2AKITA Mouse Model of Type 1 Diabetes
Rivka Dresner–Pollak, Natan Lishinsky-Fischer, Irina Gurt, Joshua Stokar, Vladislav Temkin, Pandya Shivam, G Zatarah, Joshua Milgram, Ron Shahar
Journal of the Endocrine Society · 2024 · ▲ 1 citations
Cellular senescence
Stem-cell exhaustion
Altered intercellular communication
Senolytics
Stem-cell therapy
Cell culture / in vitro
Human
Mouse
In vitro
Abstract
Abstract Disclosure: R. Dresner-Pollak: Consulting Fee; Self; Opko Biologics LTD.. Speaker; Self; Medison Pharma. N. Lishinsky: None. I. Gurt: None. J. Stokar: None. V. Temkin: None. P. Shivam: None. G. Zatarah: None. J. Milgram: None. R. Shahar: None. Skeletal fragility is a recognized complication of type 1 diabetes (T1D). The risk of hip and non-vertebral fractures is significantly higher in people living with T1D compared to age- and sex-matched non-diabetic controls and those living with type 2 diabetes (T2D). Hip fracture risk is up to six-fold higher in T1D patients; hip fractures occur 10-15 years earlier and the outcome is poorer compared to non-diabetics. Alterations in bone quality are considered major contributors to T1D-related skeletal fragility. As people with T1D live longer, there is a growing need to discover new therapeutics to reduce fracture risk. TID is associated with accelerated biological aging. Cellular senescence(definition) is a fundamental mechanism of aging. Senescent cells stop dividing, are resistant to apoptosis and acquire a distinct phenotype that includes secretome changes termed “senescence-associated secretory phenotype” (SASP). Clearing senescent cells with senolytics(definition) is recognized as a promising therapeutic approach for multiple conditions in mice and humans We explored the ability of senolytics dasatinib (D), a tyrosine kinase inhibitor, and quercetin (Q), a flavanol, present in fruit and vegetables, drug combination, to alleviate femur fragility in mice with T1D. Ins2Akita mice show a sexual dimorphic effect of the mutant Ins2 allele causing severe hyperglycemia in males. We treated Ins2Akita male and female mice and C57BL/6 wild type (WT) male mice with D + Q administered once monthly for four months beginning at age 3 months. 3-month-old Ins2Akita male mice had higher blood levels of the SASPs components HMGB1, PAI-1, MMP12, and increased gene expression of p53 and senescence effectors p16, p15 and SASPs Il1b, Mmp3, Mmp9, Mmp13, Serpineb2 at the femur diaphysis and in bone marrow mesenchymal stem cells, respectively compared to age-matched WT male mice. In vitro, exposure to glucose levels equivalent to those observed in blood in Ins2Akita male mice induced cellular senescence in IDG-SW3 osteocyte-like cells including a 4-5-fold increase in gene expression of p16INK4a, p21Cip[1], p53, double percentage of SA-β-gal+ cells and P21 protein level. Ingenuity pathway analysis of differentially expressed proteins revealed enrichment for the senescence pathway (Z=1.213; P=1.11E-05). D+Q administration did not affect bone microarchitecture at the spine (L2), distal femur metaphysis and diaphysis assessed by µCT. D+Q administration significantly increased femur resistance to fracture assessed by the 3-point-bending test by increasing whole femur work-to-fracture, the ultimate parameter of bone resistance to failure, and post-yield displacement, an index of matrix composition, organization, and bone quality in Ins2Akita males. No effect was observed in Ins2Akita females or WT male mice, indicating that the intervention is specific for T1D. Senolyitcs D+Q show promise in improving bone health in T1D. Presentation: 6/1/2024
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1210/jendso/bvae163.471
- Canonical
- link ↗
- Fetched
- 2026-10-30 MST
Cite this
APA
Dresner–Pollak, R., Lishinsky-Fischer, N., Gurt, I., Stokar, J., Temkin, V., Shivam, P., Zatarah, G., Milgram, J., & Shahar, R. (2024). 7581 Periodic Administration of Quercetin and Dasatinib Alleviates Skeletal Fragility in the INS2AKITA Mouse Model of Type 1 Diabetes. <em>Journal of the Endocrine Society</em>. https://doi.org/10.1210/jendso/bvae163.471
Vancouver
Dresner–Pollak R, Lishinsky-Fischer N, Gurt I, Stokar J, Temkin V, Shivam P, et al. 7581 Periodic Administration of Quercetin and Dasatinib Alleviates Skeletal Fragility in the INS2AKITA Mouse Model of Type 1 Diabetes. Journal of the Endocrine Society. 2024. doi:10.1210/jendso/bvae163.471.
BibTeX
@article{rivka2024Period,
title = {7581 Periodic Administration of Quercetin and Dasatinib Alleviates Skeletal Fragility in the INS2AKITA Mouse Model of Type 1 Diabetes},
author = {Rivka Dresner–Pollak and Natan Lishinsky-Fischer and Irina Gurt and Joshua Stokar and Vladislav Temkin and Pandya Shivam and G Zatarah and Joshua Milgram and Ron Shahar},
journal = {Journal of the Endocrine Society},
year = {2024},
doi = {10.1210/jendso/bvae163.471},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Journal of the Endocrine Society 2024
Open access · CC-BY
12489 Senolytics Dasatinib And Quercetin Alleviate Type 1 Diabetes-Related Cardiac Fibrosis In Male Akita Ins-/+Mice
Journal of Visualized Experiments 2017
Preprint · OA
Techniques to Induce and Quantify Cellular Senescence
Journal of Visualized Experiments 2017
Citation only
Techniques to Induce and Quantify Cellular Senescence
Journal of Clinical Investigation 2022
Open access · CC-BY
Cellular senescence and the skeleton: pathophysiology and therapeutic implications
Diabetes 2022
Citation only
1368-P: Skeletal Muscle Mitochondrial Dysfunction Contributes to Increased GDF15 Levels in Aged Mice with Insulin Resistance and Sarcopenia
Diabetologia 2006
Open access · OA